Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hey big spender!!! 5 shares bought after 8a.m. Nothing like averaging down! and topping
up your substantial holding.....yawn.
Hi Flag, I get exactly where you’re coming from - that’s why I don’t get the RNS alerts via advfn most of the time then
Flag, what’s the implication of using Reach instead of RNS?? They clearly know the differe As an RNS was issued on Jan 18th
And note that PDSB is UP. Over 6% on todays news ffs
Agreed Wilco. It’s dropped 50% on no news. It stinks!!
New study for head/neck cancers announced. Seems they are considering PDS0101 for first-line cancer treatment prior to chemo/radiation/checkpoint inhibitors which will increase the potential market exponentially. Heard Lauren Wood also referring to this possibility.
No idea why NSCI's price continues to fall, struggling to find an explanation for it
Was hoping for jobs like this for QBot. The large housing associations will have a responsibility to upgrade the insulation, hopefully lots more big contracts to come.
https://housingdigital.co.uk/amp/plus-dane-housing-appoints-q-bot-through-the-pfh-shed-framework/
Good things going on at Q-bot
Malaise due to :
1) very poor comms We all know of subsid updates or RNSs before the BOD . Suggests asleep and hardly promoting the cause
New comms person? Walbrooke Just so amateur .
2)
Investments have great potential but we have no figures on any. Proaxsis sounds great but what are yr1 yr2 yr3 estimates? does it need funding? Zero details finance wise like the rest so we linger.
They need to produce a real update not a flowery one with “its great” but no £ guidance on any investment
So yes loyal but peed off until they get a grip. Cause one day subject to 2 they are going to have to raise.
Wake up BOD and sell yourselves and the company so you can make money from your free options and put this one a proper footing
Quite a bit of buying here this morning??
Just to add to that earlier post.
Just cash and the value of PDSB almost covers our market cap. Everything else is in there for free.
Perhaps the company might like to remind investors of what we have under the hood and bring forward the results by a few weeks.
PDSB up 10% on that news. We usually lag them by a day
Published by Oppenheimer today. Predicts PDSB will outperform considerably if the market as a whole stabilises/recovers
You either believe in the underlying investments or you don't. Most of the stakes in companies they hold have a chance to add several million to the market cap, but may take years to do so.
Currently there's 21mio shares, market cap (@71p) £15mio.
They own 4.72% of PDSB which is listed - @ yesterdays close $6.11 that's worth just over £6mio
They own 100% of Proaxsis which was valued at around £7mio just over a year ago, I mean given what's happened to biotech stocks maybe that's half now? But that still gives around £10mio value just from these two holdings.
Then you have Glycotest, Sagetech, EMV, Sofant, Martlet....
Obviously Glycotest announcing something positive from clinical trials is a possible catalyst for more interest in this stock, but £5mio for all the 'rest' seems exceptional value.
My guess is that some of the money that piled in on last year's spike or the capital raise @£1.30 is getting bored/impatient/looking to invest elsewhere. Obviously DYOR etc but anything sub £1 this seems like it is great value with very good upside, but I'm not expecting it to double in days or months, of course it would be nice...
I've added below £1 including yesterday around 74p and will add a bit more if we see 60-65p, but I'm a tiny shareholder in the grand scheme of things.
The share price is a fcking joke!!
ohhh I effed up...I effed up BAD...Buying this sh*t with the hype...50% down and counting...
Looks like my great great great great great great great Grandchild 'MAY' get the initial investment back...lol
Back below price before last years spike. Time for a top up
This is defo the bottom, keep the faith!
Wasn’t there an RNS about a TR-1 holder selling off? NSCI is lumped in as a covid play I’m guessing even though that’s only a part of the co. Out of favour sector and an unloved stock. Who can call the bottom before bounce?
so why the sell off
"The achievement of this important milestone in the VERSATILE-002 Phase 2 clinical trial strengthens the evidence of our novel Versamune® platform's potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer to achieve tumor regression," commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. "The initial data solidifies our belief that PDS0101's demonstrated preclinical efficacy when combined with KEYTRUDA® has the potential to significantly improve clinical outcomes for patients with advanced HPV16-positive head and neck cancers."
Thanks Alsam
@blakieboy7 - also from LinkedIn this time from Kyberlife:
Kyberlife welcomes ProAxsis, an established, award winning commercial-stage diagnostics company with a range of assay kits designed for the specific measurement of active protease biomarkers of disease. ProAxsis has a registered CE Mark for activity-based immunoassays and has produced simplified tests ProteaseTags® & NEATstik®, among others . Aside from the provision of assays, ProAxsis also offers sample analysis services at its purpose-built laboratory facility.
Browse ProAxsis’s product and services range on Kyberlife’s Platform: https://www.kyberlife.com/